| Original language | English (US) |
|---|---|
| Pages (from-to) | 134-136 |
| Number of pages | 3 |
| Journal | Annals of the rheumatic diseases |
| Volume | 80 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2021 |
Keywords
- adalimumab
- antirheumatic agents
- arthritis
- biological therapy
- rheumatoid
- tumor necrosis factor inhibitors
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
- Biochemistry, Genetics and Molecular Biology(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. / Winthrop, Kevin L.; Citera, Gustavo; Gold, David et al.
In: Annals of the rheumatic diseases, Vol. 80, No. 1, 01.01.2021, p. 134-136.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
AU - Winthrop, Kevin L.
AU - Citera, Gustavo
AU - Gold, David
AU - Henrohn, Dan
AU - Connell, Carol A.
AU - Shapiro, Andrea B.
AU - Shi, Harry
AU - Onofrei, Alina M.
AU - Pappas, Dimitrios A.
AU - Schulze-Koops, Hendrik
N1 - Funding Information: Funding The clinical trial data analyses were funded by Pfizer Inc. The registry is sponsored by Corrona LLC, and the analyses based on secondary analysis of registry data were funded and sponsored by Pfizer Inc. Funding Information: Acknowledgements Medical writing support, under the guidance of the authors, was provided by Christina Viegelmann, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, New York, USA, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-4). Funding Information: Competing interests KLW has received grant/research support from Bristol-Myers Squibb, and consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, GSK, Pfizer Inc, Roche and UCB. GC has received grant/research support and consulting fees from AbbVie, Amgen, Eli Lilly and Company, Gema Pharma, Genzyme, Novartis and Pfizer Inc. DG, DH, CAC, ABS and HS are employees and shareholders of Pfizer Inc. AMO is an employee of Corrona LLC. DAP is an employee of Corrona LLC and has equity interest. DAP also serves on the Board of Directors for the Corrona Research Foundation and has received consulting fees from AbbVie, Genentech, Novartis, Regeneron and Roche Hellas. HSK has received grant/research support from Pfizer Inc, and consulting fees from AbbVie, Amgen, Biogen, Eli Lilly and Company, Gilead, Mylan, Pfizer Inc and Sandoz-Hexal. Corrona has been supported through contracted subscriptions in the past 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Genentech, Gilead, Janssen, Merck, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron and Sun.
PY - 2021/1/1
Y1 - 2021/1/1
KW - adalimumab
KW - antirheumatic agents
KW - arthritis
KW - biological therapy
KW - rheumatoid
KW - tumor necrosis factor inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85094673122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094673122&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2020-218992
DO - 10.1136/annrheumdis-2020-218992
M3 - Letter
C2 - 33046447
AN - SCOPUS:85094673122
SN - 0003-4967
VL - 80
SP - 134
EP - 136
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 1
ER -